Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting

Introduction: Over the last two decades, rituximab (RTX) has been widely used, albeit off-label, in primary Sjögren's syndrome (pSS). Several studies reported that B lymphocyte depletion with RTX is effective to treat some aspects within the disease spectrum, by reducing disease activity and af...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlych, Viktoriya, Di Muzio, Claudia, Alunno, Alessia, Carubbi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506066/
https://www.ncbi.nlm.nih.gov/pubmed/33015092
http://dx.doi.org/10.3389/fmed.2020.00534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506066/
https://www.ncbi.nlm.nih.gov/pubmed/33015092
http://dx.doi.org/10.3389/fmed.2020.00534

Ejemplares similares